TrialAnnals of the rheumatic diseases2009

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis.

S Visvanathan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.